Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction.
Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction.
复制标题
DOI:
10.1016/j.echo.2020.12.008
复制
发表时间:
2021-05
期刊:
影响因子:
--
通讯作者:
Patel RB
中科院分区:
文献类型:
--
作者:
Rethy L;Borlaug BA;Redfield MM;Oh JK;Shah SJ;Patel RB
Early, non-invasive identification of heart failure with preserved ejection fraction (HFpEF) patients with congestion may allow for timely tailoring of decongestive therapies. The 2016 American Society of Echocardiography / European Association of Cardiovascular Imaging guidelines provide an algorithm to assess for elevated left atrial pressure (LAP); the associations of echocardiographic LAP (echo-LAP) with clinical status and disease progression in HFpEF are unclear. We categorized participants in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in HFpEF (RELAX) trial into 1 of 4 pre-specified guideline-based echo-LAP categories: 1) normal, 2) elevated, 3) atrial fibrillation (AF) at the time of echocardiography, or 4) indeterminate. We evaluated the associations of echo-LAP categories with baseline exercise capacity, change in exercise capacity, and change in NT-proBNP over 24 weeks. Of 216 participants, 199 had mitral inflow Doppler echocardiography for LAP categorization. Participants with elevated echo-LAP (n=81) or AF (n=57) were older and had higher prevalence of kidney dysfunction. Compared with the normal echo-LAP group (n=28), elevated echo-LAP and AF were each independently associated with a greater reduction in peak oxygen consumption over 24 weeks after adjusting for baseline values and clinical covariates (β-coefficient for elevated echo-LAP: −1.55 [95% CI: −2.59, −0.51], p=0.004; β-coefficient for AF: −1.33 [95% CI: −2.49, −0.17], p=0.03). Indeterminate echo-LAP (n=33) was also independently associated with a reduction in exercise capacity at 24 weeks compared with normal echo-LAP (β-coefficient: −1.35 [95% CI: −2.51, −0.19], p=0.02). Finally, elevated echo-LAP and AF were significantly associated with increases in NT-proBNP over 24 weeks compared with normal echo-LAP. In chronic HFpEF, elevated echo-LAP and indeterminate echo-LAP, as defined by contemporary guidelines, and AF were each independently associated with a reduction in exercise capacity compared with normal echo-LAP. These findings suggest potential utility of non-invasive LAP assessment in HFpEF for tailoring treatments that decrease congestion.
登录
查看更多内容
影响因子:
5.4
作者:
Rich JD;Burns J;Freed BH;Maurer MS;Burkhoff D;Shah SJ
通讯作者:
Shah SJ
影响因子:
9.7
作者:
Redfield, Margaret M.;Borlaug, Barry A.;Braunwald, Eugene
通讯作者:
Braunwald, Eugene
DOI:
10.1161/circheartfailure.114.001192
发表时间:
2014-07
期刊:
Circulation. Heart failure
影响因子:
--
作者:
Mohammed SF;Borlaug BA;McNulty S;Lewis GD;Lin G;Zakeri R;Semigran MJ;LeWinter M;Hernandez AF;Braunwald E;Redfield MM
通讯作者:
Redfield MM
影响因子:
6.2
作者:
Lancellotti, Patrizio;Galderisi, Maurizio;Popescu, Bogdan A.
通讯作者:
Popescu, Bogdan A.
影响因子:
6.2
作者:
Lang, Roberto M.;Badano, Luigi P.;Voigt, Jens-Uwe
通讯作者:
Voigt, Jens-Uwe